Gossamer Bio (GOSS) Revenue & Revenue Breakdown
Gossamer Bio Revenue Highlights
0
Latest Revenue (Q)
$9.48M
Gossamer Bio Revenue by Period
Gossamer Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Gossamer Bio generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Gossamer Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $9.48M | -90.11% |
| 2024-06-30 | $95.84M | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $6.78M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Gossamer Bio generated $9.48M in revenue during Q3 2024, up -90.11% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Gossamer Bio Revenue Breakdown
Gossamer Bio Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 24 |
|---|---|
| License and Service | - |
Latest
Gossamer Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
| ALEC | Alector | $97.06M | $15.08M |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| KRON | Kronos Bio | $6.29M | $2.37M |
| LYRA | Lyra Therapeutics | $1.56M | $195.00K |
| FIXX | Q32 Bio | $1.16M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| BDTX | Black Diamond Therapeutics | - | - |
| XFOR | X4 Pharmaceuticals | - | $560.00K |
| GOSS | Gossamer Bio | - | $9.48M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| REPL | Replimune Group | - | - |
| PASG | Passage Bio | - | - |
| BMEA | Biomea Fusion | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| NVCT | Nuvectis Pharma | - | - |
| AKRO | Akero Therapeutics | - | - |
| FDMT | 4D Molecular Therapeutics | - | - |